Summary Molecular changes associated with breast cancer progression were characterized using the MCF-1 OF cell series. MCF-1 OF was established from fibrous mastectomy tissue of a patient without detectable cancer. In vitro treatment of MCF-1OF cells with benzo(a)pyrene resulted in a transformed subclone MCF-1OF-BP1 (BP1). Transfection of clone BP1 with T24-Hras resulted in the tumorigenic line MCF-1 OF-BP1 -Tras (BP1 -Tras). Using flow cytometry, the expression of HLA I, ERBB-2 and MUC-1 was found to be comparable in 'normal' MCF-1 OF, transformed BP1 and tumorigenic BP1-Tras cells. Glycosylated mucin is elevated in BP1 but reduced in BP1-Tras cells. Using mRNA differential display analysis, cDNA profiles of the 'normal', transformed and tumorigenic cell lines were strikingly similar, yet distinct and elevated expression of several common cDNA fragments was detected in BP1 and BP1-Tras when compared with MCF-1OF cells. These fragments were cloned and sequenced. The sequences of clones Ti-360 and C4-310 are homologous to two reported EST cDNA clones from human fetal tissue and were further characterized. Elevated expression of the genes corresponding to clones Ti -360 and C4-310 was verified using Northern blotting. High-level expression of these genes was also detected in the breast cancer cell line MCF-7 that was derived from the pleural effusion of a patient with advanced breast cancer. Therefore, specific molecular changes associated with breast cancer development were identified and may be indicators of neoplastic progression.
Neoplastic progression is a prolonged and stepwise process and tumour growth occurs after a series of molecular alterations that culminate in tumorigenesis (Foulds, 1975; Pitol and Dragan, 1991) . Particular breast lesions have been associated with increased risk of cancer development. Women with carcinoma in situ have high risk (eight to ten times) and women with atypical hyperplasia have moderate (five times) risk of developing breast cancer (Page et al, 1985; Page and Dupont, 1990) . The correlation of particular lesions with cancer development suggests that specific genetic alterations in the early lesion may dictate tumorigenesis. Identification of such molecular changes will provide tools for the diagnosis, prognosis and treatment of breast cancer.
A handful of molecular changes have been previously associated with breast cancer, including reduced level of class I major histocompatibility antigen (HLA I) (Wright et al, 1992) , amplification of ERBB-2, which is a transmembrane tyrosine kinase and a member of the epidermal growth factor receptor family (Bargmann et al, 1986; Gusterson et al, 1992; Toikkanen et al, 1992) , prolific and uniform expression of mucin as well as underglycosylation of these mucin molecules to expose the protein backbone (Girling et al, 1989; Finn et al, 1995) . Changes in HLA I and mucin may be the consequence rather than the cause of neoplastic progression. Molecular events critical to breast cancer progression besides ERBB-2 amplification are still poorly understood.
In this study, molecular alterations associated with neoplastic progression of the breast epithelial cells were characterized. A series of breast epithelial cell lines have been derived from mastectomy tissue from a 36-year-old woman (Soule et al, 1990; Paine et al, 1992) . The resected breast tissue was fibrous with a number of cysts and one focus of mild hyperplasia but without invasive or in situ carcinoma. A mortal cell line MCF-lOm derived from the tissue has a normal human diploid karyotype. A spontaneously immortalized cell line MCF-IOF was established from MCF-1Om. MCF-1OF has a near-diploid karyotype and is of luminal epithelial origin (Pauley et al, 1993) .
MCF-lOF cells were cultured with 0.2 ,ug ml-' benzo(a)pyrene at 37°C for 24 h and a clone MCF-lOF-BPl (BPI) was generated that has reduced doubling time and forms anchorage-independent colonies when grown in soft agar (Calaf and Russo, 1993; Calaf et al, 1995) . A subclone, BPI-E, developed significantly larger colonies in the agar. BP1-E cells injected into the mammary fat pads of severe combined immunodeficient (SCID) mice formed palpable lesions in 2-3 months, which were histologically adenocarcinoma but did not grow progressively. BPI cells were transfected with human T24-Hras to generate BP 1 -Tras, which produced consistent and progressively growing tumours in the mammary fat pads of SCID and nu/nu beige mice (Calaf and Russo, 1993; Calaf et al, 1995) . As BPI and BPl-Tras cells are Flow cytometric analysis of MCF-1 OF, BP1, BP1 -E, BP1 -Tras and SKBR-3 cells. Single-cell suspensions were prepared from monolayer cultures and stained with MAb W6/32, TA-1, BC-2 or SM-3 directed to class HLA, ERBB-2, glycosylated and non-glycosylated MUC-1 respectively. Normal mouse Ig (NMIg) was the negative control and FITC-conjugated goat anti-mouse IgG was the secondary antibody. L-glutamine, 10 ,ug ml-' insulin, 500 ng ml-' hydrocortisone, 100 ng ml-' cholera toxin (Calbiochem, San Diego, CA, USA), 10 ng ml-' recombinant epidermal growth factor (EGF, Calbiochem), 100 U ml-' penicillin and 100 gg ml-' streptomycin.
Human breast cancer cell line MCF-7 was established in 1973 from the pleural effusion of a patient with advanced breast adenocarcinoma (Soule et al, 1973) . MCF- mg ml-' bovine crystalline insulin (Sigma), 1 mm oxalacetic acid, 0.5 mm sodium pyruvate, 2 mM L-glutamine, 0.1 mM MEM nonessential amino acids, 100 units ml-' penicillin and 100 jig mlstreptomycin.
Flow cytometric analysis
Cells in monolayer culture were suspended by minimal treatment with trypsin-EDTA. Expression of class I HLA was determined using flow cytometry with MAb W6/32 directed to a constant region of human HLA (American Type Culture Collection). MAb TA-1, which recognizes the extracellular domain of ERBB-2, was purchased from Oncogene Research Products (Cambridge, MA, USA). MAb BC-2, which recognizes the glycosylated mucin, was obtained through Dr OJ Finn (Jerome et al, 1992) . MAb SM-3, which recognizes the underglycosylated protein core of MUC-1 protein, was a gift from Dr Joyce Taylor-Papadimitriou (Imperial Cancer Research Fund, London, UK) (Burchell et al, 1987 TaqI Northern blot analysis Polyadenylated RNA was isolated using oligo dT affinity chromatography. Northern blots were prepared essentially as described previously (Sambrook et al, 1989 
MRNA differential display
The enhanced anchorage-independent growth and tumorigenicity of BPl-Tras cells indicated that critical genetic events occurred after benzo(a)pyrene treatment and T24-Hracis transfection (Calaf and Russo, 1993 CCATTGCCAAAAGGTTTTACTGTCTTAAAGCTGTCTTTCTGAGATCTAATTCCAAGGACT * * * * * * * * * * * * * * * * * * * * * * * A ir * * X * * X * * X * * * * X * X * * * * * * X * X * * * * * * The sequence of TI-360 ( Figure 5 ) was determined by automatic sequencing. Homology with previously described cDNA sequence was analysed using the computer program 'Basic Local Alignment Search Tool' (BLAST) to directly access the database including the Genebank in the National Center for Biotechnology Information (NCBI). TI-360 was highly homologous with the sequence of a previously described EST cDNA clone 72720 from human fetal spleen with unknown function. Because the reported sequence of clone 72720 was incomplete, this clone was purchased from the Genetics Institute, resequenced and was found to have >99% homology with the sequence of TI-360 ( Figure 5 ). The sequence of clone 72720 added 285 bp to the 5' end of clone TI-360. Northern hybridization of poly-A RNA from BPI, BPITras and MCF-7 with the purchased 72720 probe produced the same 7.5 and 5.5 kb bands (not shown), supporting the identical nature of clone T1-360 and 72720. Therefore, the transformation of MCF-I OF cells is associated with a sustained, elevated expression of mRNA containing the sequence of T 1-360 or clone 72720. Using the same BLAST program, the sequence of clone C4-310 showed >95% homology with another EST cDNA clone 239655 also from human fetal spleen (Figure 6 ). The sequence of 239655 added 92 bp to the 5' end of the C4-310 sequence. As T 1 -360, C4-310 as well as the reported EST clones were all identified using the primer 5'-TTTTTTTTTTTTMN-3' and another random primer, the sequences represent the 3' termini with polyadenylation signal and may contain but are not limited to the non-coding region. Therefore, mRNAs containing TI-360 and C4-310 sequences were expressed in the fetal tissue and were elevated in the transformed breast epithelial cells.
DISCUSSION
Molecular changes that occurred during neoplastic progression of breast epithelial cells were examined. Specific molecular changes previously described in breast cancer cells included reduced HLA 1 (Wright et al, 1992) , amplified ERBB-2 (Bargmann et al, 1986; Gusterson et al, 1992; Toikkanen et al, 1992) and uniformly distributed, underglycosylated mucin (Girling et al, 1989; Finn et al, 1995) . Changes in HLA I and ERBB-2 were not detected in British Journal of Cancer (1998) MCF-IOF cell series. Because racs is activated downstream of ERBB-2 (Xie et al., 1995) , overexpression of ras may bypass the oncogenic activity of ERBB-2. It is not surprising that tumorigenic BPl-Tras, which was derived from BPl by transfection with T24-Hras, did not have ERBB-2 amplification. Increased expression of mucin was found on BP1 and BPI-E cells and was a likely consequence of transformation. Interestingly, mucin overexpression was not observed in BP1-Tras cells, suggesting that increased mucin is not essential for tumorigenesis and may be lost with further neoplastic progression. Mucin on breast cancer cells is often underglycosylated, thus exposing the protein backbone (MUC-1). The underglycosylated MUC-1, however, was not detected in any of the MCF-1OF-derived cells, suggesting that under-glycosylation of MUC-I is not essential for neoplastic progression in vitro.
The strikingly similar profiles of cDNA fragments from MCF-I OF cell series were expected because of their common origin. The changes in mRNA expression detected by differential display analysis, therefore, probably represented critical events that occurred during neoplastic progression. It is of interest that several cDNA fragments were enhanced in BP1 -E but not in tumorigenic BPl-Tras cells (Figure 3 ). The cause of this transient complexity in gene expression can only be speculated. It is possible that treatment with benzo(a)pyrene activated many normally quiescent genes. Only a fraction of those gene products could provide growth or survival advantages and enhanced expression of these genes was expected in both transformed and tumorigenic cells. Therefore, cDNA fragments that demonstrated elevated expression in both BPI and BPI-Tras were identified and characterized. Approximately 20 cDNA fragments were clearly elevated in both BPl and BPI-Tras cells, and 16 of them were cloned and sequenced. Homologous sequences to clones T 1-360 and C4-3 10 were found by BLAST analysis in the NCBI database and were further characterized. Increased expression of mRNA species containing Tl-360 or C4-3 10 sequences was verified using Northern blot hybridization. These RNA species were of low abundance because their detection by Northern blotting required the use of poly-A RNA and prolonged exposure time (4-7 days). As many genes that mediate critical cellular functions including signal transduction are expressed at low levels, TI-360 and C4-310 may represent such genes. Detection of changes in low-abundance RNA is possible only in cell series from the same origin such as the MCF-1OF series. In this study, expression of T1-360-and C4-3 10-related genes was elevated in BP1 and BP 1 -Tras cell lines when compared with the parental MCF-1 OF cell. The increased gene expression is correlated with enhanced anchorageindependent growth of BP1-Tras>BPl>MCF-10 F (Calaf and Russo, 1993; Calaf et al, 1995 ). Importantly, high-level expression of genes containing TI-360 and C4-3 10 sequences was also detected in a human breast cancer cell line MCF-7, supporting their roles in human breast cancer development. Further characterization of these genes will provide useful tools in dissecting the molecular events during neoplastic progression.
